{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:46:25Z","timestamp":1768826785873,"version":"3.49.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Baker Department of Cardiometabolic Health","award":["seed funding"],"award-info":[{"award-number":["seed funding"]}]},{"name":"Baker Department of Cardiometabolic Health","award":["seed funding"],"award-info":[{"award-number":["seed funding"]}]},{"DOI":"10.13039\/501100000971","name":"Diabetes Australia","doi-asserted-by":"crossref","award":["Baker Trust Alice Baker and Eleanor Shaw Gender Equity Fellowship"],"award-info":[{"award-number":["Baker Trust Alice Baker and Eleanor Shaw Gender Equity Fellowship"]}],"id":[{"id":"10.13039\/501100000971","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","award":["Operational Infrastructure Scheme"],"award-info":[{"award-number":["Operational Infrastructure Scheme"]}],"id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1146128"],"award-info":[{"award-number":["1146128"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Preeclampsia is a severe pregnancy complication associated with substantial injury to systemic vasculature, major organs, and the feto-placental unit, with an approximate mortality rate of 76,000 pregnant women and 500,000 babies each year. Preeclampsia results in up to five-fold increased risk of cardiovascular disease. There is currently no cure and limited treatment options for preeclampsia and its long-term effects. In this study, we modelled preeclampsia in the mouse via nitric oxide blockade and examined the effect of therapeutic intervention during pregnancy (esomeprazole) and postpartum (eplerenone) on indices of cardiovascular health. Pregnant CBA x C57BL\/6 mice received 50\u00a0mg\/kg\/day N(\u03c9)-nitro-<jats:sc>L<\/jats:sc>-arginine methyl ester to induce a preeclampsia-like phenotype. Mice were treated with either 12.5\u00a0mg\/kg\/day esomeprazole during pregnancy, 55.5\u00a0mg\/kg\/day eplerenone during the postpartum period, or both esomeprazole and eplerenone in sequence. Mice were hypertensive during pregnancy, fetal growth was restricted by 10%, and maternal vasoactivity was impaired at 5-weeks postpartum. Eplerenone treatment (\u00b1\u2009esomeprazole) reduced vasoconstriction at 5-weeks postpartum and enhanced vasorelaxation at 5- and 10-weeks postpartum, supporting improved cardiovascular indices in the medium to long term postpartum period. Postpartum eplerenone treatment may be beneficial in mitigating consequent cardiovascular disease risk following a pregnancy complicated by preeclampsia.<\/jats:p>","DOI":"10.1038\/s41598-025-02475-0","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T03:37:18Z","timestamp":1748317038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy"],"prefix":"10.1038","volume":"15","author":[{"given":"Natalie K.","family":"Binder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"de Alwis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Beard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca R.","family":"Fato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morag J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie J.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2475_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.semperi.2009.02.010","volume":"33","author":"L Duley","year":"2009","unstructured":"Duley, L. The global impact of pre-eclampsia and eclampsia. Semin. Perinatol. 33, 130\u2013137. https:\/\/doi.org\/10.1053\/j.semperi.2009.02.010 (2009).","journal-title":"Semin. Perinatol."},{"key":"2475_CR2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1097\/AOG.0b013e3181a45b25","volume":"113","author":"EV Kuklina","year":"2009","unstructured":"Kuklina, E. V., Ayala, C. & Callaghan, W. M. Hypertensive disorders and severe obstetric morbidity in the united States. Obstet. Gynecol. 113, 1299\u20131306. https:\/\/doi.org\/10.1097\/AOG.0b013e3181a45b25 (2009).","journal-title":"Obstet. Gynecol."},{"key":"2475_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/siny.2000.0023","volume":"5","author":"F Paruk","year":"2000","unstructured":"Paruk, F. & Moodley, J. Maternal and neonatal outcome in early- and late-onset pre-eclampsia. Semin. Neonatol. 5, 197\u2013207. https:\/\/doi.org\/10.1053\/siny.2000.0023 (2000).","journal-title":"Semin. Neonatol."},{"key":"2475_CR4","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.3390\/cells10113055","volume":"10","author":"MA Opichka","year":"2021","unstructured":"Opichka, M. A., Rappelt, M. W., Gutterman, D. D., Grobe, J. L. & McIntosh, J. J. Vascular dysfunction in preeclampsia. Cells 10, 3055 (2021).","journal-title":"Cells"},{"key":"2475_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nm1429","volume":"12","author":"S Venkatesha","year":"2006","unstructured":"Venkatesha, S. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642\u2013649. https:\/\/doi.org\/10.1038\/nm1429 (2006).","journal-title":"Nat. Med."},{"key":"2475_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physiol.00043.2008","volume":"24","author":"A Wang","year":"2009","unstructured":"Wang, A., Rana, S. &  Karumanchi, S. A. Preeclampsia: The role of angiogenic factors in its pathogenesis. Physiology 24, 147\u2013158. https:\/\/doi.org\/10.1152\/physiol.00043.2008 (2009).","journal-title":"Physiology"},{"key":"2475_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.placenta.2009.02.009","volume":"30","author":"GJ Burton","year":"2009","unstructured":"Burton, G. J., Woods, A. W., Jauniaux, E. & Kingdom, J. C. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30, 473\u2013482. https:\/\/doi.org\/10.1016\/j.placenta.2009.02.009 (2009).","journal-title":"Placenta"},{"key":"2475_CR8","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/jcm8101625","volume":"8","author":"R Fox","year":"2019","unstructured":"Fox, R. et al. Risk factors, diagnosis, management, and the cardiovascular impact on the offspring. J. Clin. Med. 8, 1625. https:\/\/doi.org\/10.3390\/jcm8101625 (2019).","journal-title":"J. Clin. Med."},{"key":"2475_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/bs.apha.2016.04.008","volume":"77","author":"JS Possomato-Vieira","year":"2016","unstructured":"Possomato-Vieira, J. S. & Khalil, R. A. Mechanisms of endothelial dysfunction in hypertensive pregnancy and preeclampsia. Adv. Pharmacol. 77, 361\u2013431. https:\/\/doi.org\/10.1016\/bs.apha.2016.04.008 (2016).","journal-title":"Adv. Pharmacol."},{"key":"2475_CR10","doi-asserted-by":"publisher","unstructured":"Germain, A. M. et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (Dallas, Tex.: 1979) 49, 90\u201395. https:\/\/doi.org\/10.1161\/01.HYP.0000251522.18094.d4 (2007).","DOI":"10.1161\/01.HYP.0000251522.18094.d4"},{"key":"2475_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/circresaha.118.313276","volume":"124","author":"S Rana","year":"2019","unstructured":"Rana, S., Lemoine, E., Granger, J. P. & Karumanchi, S. A. Preeclampsia: Pathophysiology, challenges, and perspectives. Circ. Res. 124, 1094\u20131112. https:\/\/doi.org\/10.1161\/circresaha.118.313276 (2019).","journal-title":"Circ. Res."},{"key":"2475_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/bmj.323.7323.1213","volume":"323","author":"HU Irgens","year":"2001","unstructured":"Irgens, H. U., Roberts, J. M., Reis\u00e6ter, L., Irgens, L. M. & Lie, R. T. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study Pre-eclampsia and cardiovascular disease later in life: who is at risk? BMJ 323, 1213\u20131217. https:\/\/doi.org\/10.1136\/bmj.323.7323.1213 (2001).","journal-title":"BMJ"},{"key":"2475_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1081\/PRG-100100136","volume":"19","author":"R Mar\u00edn","year":"2000","unstructured":"Mar\u00edn, R. et al. Long-term prognosis of hypertension in pregnancy. Hypertens. Pregnancy. 19, 199\u2013209. https:\/\/doi.org\/10.1081\/PRG-100100136 (2000).","journal-title":"Hypertens. Pregnancy"},{"key":"2475_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/HYPERTENSIONAHA.111.176537","volume":"58","author":"K Melchiorre","year":"2011","unstructured":"Melchiorre, K., Sutherland, G. R., Liberati, M. & Thilaganathan, B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension 58, 709\u2013715. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.176537 (2011).","journal-title":"Hypertension"},{"key":"2475_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/heartjnl-2018-313453","volume":"105","author":"L Benschop","year":"2019","unstructured":"Benschop, L., Duvekot, J. J. & van Roeters, J. E. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 105, 1273\u20131278. https:\/\/doi.org\/10.1136\/heartjnl-2018-313453 (2019).","journal-title":"Heart"},{"key":"2475_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/HJH.0b013e328335c29a","volume":"28","author":"VD Garovic","year":"2010","unstructured":"Garovic, V. D. et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J. Hypertens. 28, 826\u2013833. https:\/\/doi.org\/10.1097\/HJH.0b013e328335c29a (2010).","journal-title":"J. Hypertens."},{"key":"2475_CR17","doi-asserted-by":"publisher","first-page":"m3502","DOI":"10.1136\/bmj.m3502","volume":"371","author":"K Okoth","year":"2020","unstructured":"Okoth, K. et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ (Clin. Res. ed.). 371, m3502. https:\/\/doi.org\/10.1136\/bmj.m3502 (2020).","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"2475_CR18","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jama.2021.8551","volume":"326","author":"JT Henderson","year":"2021","unstructured":"Henderson, J. T., Vesco, K. K., Senger, C. A., Thomas, R. G. & Redmond, N. Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US preventive services task force. JAMA 326, 1192\u20131206. https:\/\/doi.org\/10.1001\/jama.2021.8551 (2021).","journal-title":"JAMA"},{"key":"2475_CR19","doi-asserted-by":"publisher","unstructured":"Duley, L., Meher, S., Hunter, K. E., Seidler, A. L. & Askie, L. M. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD004659.pub3 (2019).","DOI":"10.1002\/14651858.CD004659.pub3"},{"key":"2475_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.placenta.2020.08.022","volume":"102","author":"N de Alwis","year":"2020","unstructured":"de Alwis, N. et al. Novel approaches to combat preeclampsia: from new drugs to innovative delivery. Placenta 102, 10\u201316. https:\/\/doi.org\/10.1016\/j.placenta.2020.08.022 (2020).","journal-title":"Placenta"},{"key":"2475_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.semperi.2006.01.008","volume":"30","author":"BM Sibai","year":"2006","unstructured":"Sibai, B. M. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin. Perinatol. 30, 16\u201319. https:\/\/doi.org\/10.1053\/j.semperi.2006.01.008 (2006).","journal-title":"Semin. Perinatol."},{"key":"2475_CR22","doi-asserted-by":"publisher","first-page":"F1315","DOI":"10.1152\/ajprenal.00071.2020","volume":"318","author":"HR Turbeville","year":"2020","unstructured":"Turbeville, H. R. & Sasser, J. M. Preeclampsia beyond pregnancy: long-term consequences for mother and child. Am. J. Physiol.-Ren. Physiol. 318, F1315\u2013F1326. https:\/\/doi.org\/10.1152\/ajprenal.00071.2020 (2020).","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"2475_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","volume":"116","author":"CM Ferrario","year":"2015","unstructured":"Ferrario, C. M. & Schiffrin, E. L. Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circul. Res. 116, 206\u2013213. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.302706 (2015).","journal-title":"Circul. Res."},{"key":"2475_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 341, 709\u2013717. https:\/\/doi.org\/10.1056\/nejm199909023411001 (1999).","journal-title":"N. Engl. J. Med."},{"key":"2475_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2010","unstructured":"Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2475_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4103\/jpbs.JPBS_338_19","volume":"12","author":"A Pradhan","year":"2020","unstructured":"Pradhan, A., Vohra, S. & Sethi, R. Eplerenone: The multifaceted drug in cardiovascular Pharmacology. J. Pharm. Bioallied Sci. 12, 381\u2013390. https:\/\/doi.org\/10.4103\/jpbs.JPBS_338_19 (2020).","journal-title":"J. Pharm. Bioallied Sci."},{"key":"2475_CR27","doi-asserted-by":"publisher","unstructured":"Brown, N. J. Eplerenone. Circulation 107, 2512\u20132518. https:\/\/doi.org\/10.1161\/01.CIR.0000071081.35693.9A (2003).","DOI":"10.1161\/01.CIR.0000071081.35693.9A"},{"key":"2475_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1042\/cs20171525","volume":"132","author":"WC Valinsky","year":"2018","unstructured":"Valinsky, W. C., Touyz, R. M. & Shrier, A. Aldosterone, SGK1, and ion channels in the kidney. Clin. Sci. (Lond). 132, 173\u2013183. https:\/\/doi.org\/10.1042\/cs20171525 (2018).","journal-title":"Clin. Sci. (Lond)"},{"key":"2475_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.ackd.2013.01.012","volume":"20","author":"KL Cheung","year":"2013","unstructured":"Cheung, K. L. & Lafayette, R. A. Renal physiology of pregnancy. Adv. Chronic Kidney Dis. 20, 209\u2013214. https:\/\/doi.org\/10.1053\/j.ackd.2013.01.012 (2013).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"2475_CR30","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3109\/14767058.2014.951627","volume":"28","author":"MN Uddin","year":"2015","unstructured":"Uddin, M. N. et al. Suppression of aldosterone and progesterone in preeclampsia. J. Matern. Fetal Neonatal Med. 28, 1296\u20131301. https:\/\/doi.org\/10.3109\/14767058.2014.951627 (2015).","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"2475_CR31","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/j.1523-1755.2004.66031.x","volume":"66","author":"K Shojaati","year":"2004","unstructured":"Shojaati, K. et al. Evidence for compromised aldosterone synthase enzyme activity in preeclampsia. Kidney Int. 66, 2322\u20132328. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.66031.x (2004).","journal-title":"Kidney Int."},{"key":"2475_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/vhrm.S33759","volume":"9","author":"JL Guichard","year":"2013","unstructured":"Guichard, J. L., Clark, D. 3, Calhoun, D. A., Ahmed, M. & rd, & I. Aldosterone receptor antagonists: current perspectives and therapies. Vasc. Health Risk Manag. 9, 321\u2013331. https:\/\/doi.org\/10.2147\/vhrm.S33759 (2013).","journal-title":"Vasc. Health Risk Manag."},{"key":"2475_CR33","doi-asserted-by":"publisher","first-page":"e012","DOI":"10.1621\/nrs.05012","volume":"5","author":"S Viengchareun","year":"2007","unstructured":"Viengchareun, S. et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl. Recept Signal. 5, e012. https:\/\/doi.org\/10.1621\/nrs.05012 (2007).","journal-title":"Nucl. Recept Signal."},{"key":"2475_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","volume":"53","author":"JW Funder","year":"2009","unstructured":"Funder, J. W. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53, 286\u2013290. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.119966 (2009).","journal-title":"Hypertension"},{"key":"2475_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","volume":"34","author":"NS Ferreira","year":"2021","unstructured":"Ferreira, N. S., Tostes, R. C., Paradis, P. &  Schiffrin, E. L. Aldosterone, inflammation, immune system, and hypertension. Am. J. Hypertens. 34, 15\u201327. https:\/\/doi.org\/10.1093\/ajh\/hpaa137 (2021).","journal-title":"Am. J. Hypertens."},{"key":"2475_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/hypertensionaha.113.01803","volume":"63","author":"AJ Rickard","year":"2014","unstructured":"Rickard, A. J. et al. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone\/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertens. (Dallas Tex. : 1979). 63, 1033\u20131040. https:\/\/doi.org\/10.1161\/hypertensionaha.113.01803 (2014).","journal-title":"Hypertens. (Dallas Tex. : 1979)"},{"key":"2475_CR37","doi-asserted-by":"crossref","unstructured":"Keidar, S. et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in Apolipoprotein E\u2013Deficient mice. J. Cardiovasc. Pharmacol. 41 (2003).","DOI":"10.1097\/00005344-200306000-00019"},{"key":"2475_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","volume":"26","author":"J Suzuki","year":"2006","unstructured":"Suzuki, J. et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler. Thromb. Vasc. Biol. 26, 917\u2013921. https:\/\/doi.org\/10.1161\/01.ATV.0000204635.75748.0f (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2475_CR39","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl. J. Med. 348, 1309\u20131321. https:\/\/doi.org\/10.1056\/NEJMoa030207 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2475_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0149-2918(00)80032-6","volume":"22","author":"J Horn","year":"2000","unstructured":"Horn, J. The proton-pump inhibitors: similarities and differences. Clin. Ther. 22, 266\u2013280. https:\/\/doi.org\/10.1016\/S0149-2918(00)80032-6 (2000).","journal-title":"Clin. Ther."},{"key":"2475_CR41","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/ajg.2009.122","volume":"104","author":"SK Gill","year":"2009","unstructured":"Gill, S. K., O\u2019Brien, L., Einarson, T. R. & Koren, G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am. J. Gastroenterol. 104, 1541\u20131545. https:\/\/doi.org\/10.1038\/ajg.2009.122 (2009). quiz 1540, 1546.","journal-title":"Am. J. Gastroenterol."},{"key":"2475_CR42","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1002689","volume":"363","author":"B Pasternak","year":"2010","unstructured":"Pasternak, B. & Hviid, A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N. Engl. J. Med. 363, 2114\u20132123. https:\/\/doi.org\/10.1056\/NEJMoa1002689 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2475_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/hypertensionaha.117.09741","volume":"70","author":"L Saleh","year":"2017","unstructured":"Saleh, L. et al. Low soluble Fms-Like tyrosine Kinase-1, endoglin, and Endothelin-1 levels in women with confirmed or suspected preeclampsia using proton pump inhibitors. Hypertens. (Dallas Tex. : 1979). 70, 594\u2013600. https:\/\/doi.org\/10.1161\/hypertensionaha.117.09741 (2017).","journal-title":"Hypertens. (Dallas Tex. : 1979)"},{"key":"2475_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/hypertensionaha.116.08408","volume":"69","author":"K Onda","year":"2017","unstructured":"Onda, K. et al. Proton pump inhibitors decrease soluble fms-Like tyrosine Kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertens. (Dallas Tex. : 1979). 69, 457\u2013468. https:\/\/doi.org\/10.1161\/hypertensionaha.116.08408 (2017).","journal-title":"Hypertens. (Dallas Tex. : 1979)"},{"key":"2475_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejogrb.2018.05.004","volume":"225","author":"AN Shafik","year":"2018","unstructured":"Shafik, A. N., Khattab, M. A. & Osman, A. H. Magnesium sulfate versus Esomeprazole impact on the neonates of preeclamptic rats. Eur. J. Obstet. Gynecol. Reprod. Biol. 225, 236\u2013242. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.05.004 (2018).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"2475_CR46","doi-asserted-by":"crossref","unstructured":"Cluver, C. A. et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. Am. J. Obstet. Gynecol. 219 388.e381\u2013388.e317 (2018).","DOI":"10.1016\/j.ajog.2018.07.019"},{"key":"2475_CR47","doi-asserted-by":"publisher","unstructured":"Fato, B. R. et al. Serum collected from preeclamptic pregnancies drives vasoconstriction of human omental Arteries-A novel ex vivo model of preeclampsia for therapeutic development. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms231810852 (2022).","DOI":"10.3390\/ijms231810852"},{"key":"2475_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.placenta.2023.01.001","volume":"132","author":"NK Binder","year":"2023","unstructured":"Binder, N. K. et al. Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model. Placenta 132, 20\u201326. https:\/\/doi.org\/10.1016\/j.placenta.2023.01.001 (2023).","journal-title":"Placenta"},{"key":"2475_CR49","doi-asserted-by":"publisher","unstructured":"de Alwis, N. et al. Assessment of the proton pump inhibitor, Esomeprazole magnesium hydrate and trihydrate, on pathophysiological markers of preeclampsia in preclinical human models of disease. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms23179533 (2022).","DOI":"10.3390\/ijms23179533"},{"key":"2475_CR50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","volume":"27","author":"LA Magee","year":"2022","unstructured":"Magee, L. A. et al. The 2021 international society for the study of hypertension in pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 27, 148\u2013169. https:\/\/doi.org\/10.1016\/j.preghy.2021.09.008 (2022).","journal-title":"Pregnancy Hypertens."},{"key":"2475_CR51","doi-asserted-by":"publisher","unstructured":"de Alwis, N. et al. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health. Life Sci. Alliance. 5 https:\/\/doi.org\/10.26508\/lsa.202201517 (2022).","DOI":"10.26508\/lsa.202201517"},{"key":"2475_CR52","doi-asserted-by":"publisher","unstructured":"de Alwis, N. et al. Actions of Esomeprazole on the maternal vasculature in lean and obese pregnant mice with impaired nitric oxide synthesis: A model of preeclampsia. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms23158185 (2022).","DOI":"10.3390\/ijms23158185"},{"key":"2475_CR53","doi-asserted-by":"publisher","first-page":"H77","DOI":"10.1152\/ajpheart.01021.2020","volume":"321","author":"CF Wenceslau","year":"2021","unstructured":"Wenceslau, C. F. et al. Guidelines for the measurement of vascular function and structure in isolated arteries and veins. Am. J. Physiol. Heart Circ. Physiol. 321, H77\u2013h111. https:\/\/doi.org\/10.1152\/ajpheart.01021.2020 (2021).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2475_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1530\/joe-20-0161","volume":"246","author":"GSY Ong","year":"2020","unstructured":"Ong, G. S. Y. et al. Novel mineralocorticoid receptor mechanisms regulate cardiac tissue inflammation in male mice. J. Endocrinol. 246, 123\u2013134. https:\/\/doi.org\/10.1530\/joe-20-0161 (2020).","journal-title":"J. Endocrinol."},{"key":"2475_CR55","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1210\/en.2016-1040","volume":"157","author":"JZ Shen","year":"2016","unstructured":"Shen, J. Z. et al. Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages. Endocrinology. 157, 3213\u20133223. https:\/\/doi.org\/10.1210\/en.2016-1040 (2016).","journal-title":"Endocrinology"},{"key":"2475_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000158978","volume":"30","author":"KL Christensen","year":"1993","unstructured":"Christensen, K. L. & Mulvany, M. J. Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats. J. Vasc. Res. 30, 73\u201379. https:\/\/doi.org\/10.1159\/000158978 (1993).","journal-title":"J. Vasc. Res."},{"key":"2475_CR57","doi-asserted-by":"publisher","first-page":"H639","DOI":"10.1152\/ajpheart.00617.2011","volume":"303","author":"J van Drongelen","year":"2012","unstructured":"van Drongelen, J., Hooijmans, C. R., Lotgering, F. K., Smits, P. & Spaanderman, M. E. Adaptive changes of mesenteric arteries in pregnancy: a meta-analysis. Am. J. Physiol. Heart Circ. Physiol. 303, H639\u2013657. https:\/\/doi.org\/10.1152\/ajpheart.00617.2011 (2012).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2475_CR58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","volume":"152","author":"S Dutta","year":"2016","unstructured":"Dutta, S. & Sengupta, P. Men and mice: relating their ages. Life Sci. 152, 244\u2013248. https:\/\/doi.org\/10.1016\/j.lfs.2015.10.025 (2016).","journal-title":"Life Sci."},{"key":"2475_CR59","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/eurheartj\/ehaa1044","volume":"42","author":"A Maas","year":"2021","unstructured":"Maas, A. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J. 42, 967\u2013984. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1044 (2021).","journal-title":"Eur. Heart J."},{"key":"2475_CR60","doi-asserted-by":"publisher","unstructured":"Cheng, Y. J. et al. Systolic blood pressure and cardiovascular risk in normotensive adults. Mayo Clin. Proc. 98, 386\u2013397. https:\/\/doi.org\/10.1016\/j.mayocp.2022.10.011 (2023).","DOI":"10.1016\/j.mayocp.2022.10.011"},{"key":"2475_CR61","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1753944708094227","volume":"2","author":"I Craici","year":"2008","unstructured":"Craici, I., Wagner, S. & Garovic, V. D. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther. Adv. Cardiovasc. Dis. 2, 249\u2013259. https:\/\/doi.org\/10.1177\/1753944708094227 (2008).","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"2475_CR62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/CIRCULATIONAHA.110.943407","volume":"122","author":"PR Romundstad","year":"2010","unstructured":"Romundstad, P. R., Magnussen, E. B., Smith, G. D. & Vatten, L. J. Hypertension in pregnancy and later cardiovascular risk. Circulation. 122, 579\u2013584. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.943407 (2010).","journal-title":"Circulation"},{"key":"2475_CR63","doi-asserted-by":"publisher","unstructured":"Mueller, K. B. et al. Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure. Hypertension (Dallas, Tex.: 1979). 66, 988\u2013997. https:\/\/doi.org\/10.1161\/hypertensionaha.115.06172 (2015).","DOI":"10.1161\/hypertensionaha.115.06172"},{"key":"2475_CR64","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/hypertensionaha.114.01997","volume":"63","author":"IZ Jaffe","year":"2014","unstructured":"Jaffe, I. Z. & Jaisser, F. Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction. Hypertens. (Dallas Tex. : 1979). 63, 915\u2013917. https:\/\/doi.org\/10.1161\/hypertensionaha.114.01997 (2014).","journal-title":"Hypertens. (Dallas Tex. : 1979)"},{"key":"2475_CR65","doi-asserted-by":"publisher","first-page":"H175","DOI":"10.1152\/ajpheart.00660.2006","volume":"292","author":"D Susic","year":"2007","unstructured":"Susic, D., Varagic, J., Ahn, J., Matavelli, L. & Frohlich, E. D. Long-term mineralocorticoid receptor Blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am. J. Physiol. Heart Circ. Physiol. 292, H175\u2013179. https:\/\/doi.org\/10.1152\/ajpheart.00660.2006 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2475_CR66","unstructured":"Atwa, K., Ibrahim, Z., Elshaer, M., Taha, O. & Aboelroose, A. J. A. J. O. G. Role of esomeprazole in early preeclampsia: a randomized controlled trial.  8, 1189 (2021)."},{"key":"2475_CR67","doi-asserted-by":"publisher","first-page":"j3078","DOI":"10.1136\/bmj.j3078","volume":"358","author":"I Behrens","year":"2017","unstructured":"Behrens, I. et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ 358, j3078. https:\/\/doi.org\/10.1136\/bmj.j3078 (2017).","journal-title":"BMJ"},{"key":"2475_CR68","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1097\/AOG.0b013e3181c14e3e","volume":"114","author":"D Berks","year":"2009","unstructured":"Berks, D., Steegers, E. A. P., Molas, M. & Visser, W. Resolution of hypertension and proteinuria after preeclampsia. Obstet. Gynecol. 114, 1307\u20131314. https:\/\/doi.org\/10.1097\/AOG.0b013e3181c14e3e (2009).","journal-title":"Obstet. Gynecol."},{"key":"2475_CR69","doi-asserted-by":"crossref","unstructured":"Mangos, G. J., Spaan, J. J., Pirabhahar, S. & Brown, M. A. Markers of cardiovascular disease risk after hypertension in pregnancy. J. Hypertens. 30 (2012).","DOI":"10.1097\/HJH.0b013e32834e5ac7"},{"key":"2475_CR70","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2215\/cjn.10641012","volume":"8","author":"MK Sandvik","year":"2013","unstructured":"Sandvik, M. K., Hallan, S., Svarstad, E. & Vikse, B. E. Preeclampsia and prevalence of microalbuminuria 10 years later. Clin. J. Am. Soc. Nephrol. 8, 1126\u20131134. https:\/\/doi.org\/10.2215\/cjn.10641012 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2475_CR71","doi-asserted-by":"publisher","first-page":"426","DOI":"10.14744\/semb.2020.56650","volume":"55","author":"U Coban","year":"2021","unstructured":"Coban, U., Takmaz, T., Unyeli, O. D. & Ozdemir, S. Adverse outcomes of preeclampsia in previous and subsequent pregnancies and the risk of recurrence. Sisli Etfal Hastanesi Tip Bulteni. 55, 426\u2013431. https:\/\/doi.org\/10.14744\/semb.2020.56650 (2021).","journal-title":"Sisli Etfal Hastanesi Tip Bulteni"},{"key":"2475_CR72","doi-asserted-by":"publisher","first-page":"b2255","DOI":"10.1136\/bmj.b2255","volume":"338","author":"S Hern\u00e1ndez-D\u00edaz","year":"2009","unstructured":"Hern\u00e1ndez-D\u00edaz, S., Toh, S. & Cnattingius, S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ (Clinical Res. ed.). 338, b2255. https:\/\/doi.org\/10.1136\/bmj.b2255 (2009).","journal-title":"BMJ (Clin. Res. ed.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02475-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02475-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02475-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:02:41Z","timestamp":1748361761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02475-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2475"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02475-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18455"}}